.png)
SummaryBelgium is the quiet exception in European drug pricing. The published price is the ex-factory price, it is official, it covers reimbursed and non-reimbursed products, and one of the two sources updates daily. No VAT to strip out, no margin scale to invert, no band basis to prove. For a European price dataset that makes Belgium one of the cheapest countries to get right, and the remaining work sits in redistribution rights and in one unstable download link.
The national health insurance institute publishes the list of reimbursed specialities as a monthly spreadsheet. On 5 September 2026 the file returned HTTP 200 at 13,486,144 bytes, from a stable address. The institute's data is explicitly free to use.
The authentic source for medicines, known as SAM, publishes a daily XML export. It carries two price fields at manufacturer level, an official ex-factory price and a real ex-factory price, alongside a structured field for the pack quantity. Crucially it covers non-reimbursed products as well, which most European price sources do not.
| Property | Insurance institute list | Daily XML export |
|---|---|---|
| Price level | Ex-factory | Ex-factory, official and real |
| Rhythm | Monthly | Daily |
| Coverage | Reimbursed | Reimbursed and non-reimbursed |
| Pack code | CNK | CNK |
| Pack size | In the file | Structured field |
| Link stability | Stable, verified | Version parameter, unstable |
Our own assessment ranks Belgium at the top of the European field for pack level matching. The reason is unglamorous: there is a dedicated field for the pack quantity, and the national code is pack specific. That is all it takes.
There is no GTIN in the Belgian files. It is not needed. Where a national code is pack specific and the quantity is a structured field rather than free text, a join is deterministic and a parser is unnecessary. Compare that with countries where the pack size hides inside a product designation with inconsistent grammar, and the difference in implementation effort is measured in weeks.
The daily export is reached through a download address that carries a version and schema parameter. The version named in our source material returned HTTP 404 on 5 September 2026, and the same address without the parameter returned HTTP 400. Both results were reproduced on 14 September 2026, which is why we do not print the address here.
The operational consequence is specific: the current version has to be determined before each retrieval. A hard coded URL will work until a schema version is retired, and then it will fail silently for anyone who does not monitor the status code. The monthly institute file, by contrast, is stable and was verified at its full size.
Build the pipeline so that the stable monthly file is the fallback and the daily export is the preferred source when it resolves. That gives currency without making the whole country dependent on a moving link.
Belgium is legally comfortable in one half and unfinished in the other.
The insurance institute's data is explicitly free. For the daily export, free access is assured but onward distribution is not explicitly granted. That distinction is the entire commercial question for a data platform: using data internally and redistributing it to paying customers are different rights, and silence in a set of terms is not permission.
The correct step is a written confirmation from the publishing body rather than an assumption, and the question should be asked precisely: not whether the data may be used, but whether it may be redistributed as part of a commercial product after processing.
For non-reimbursed medicines a second route exists through the pharmacotherapeutic reference work, which publishes a consumer price excluding tax. Getting from there to the manufacturer level takes two steps, both capped:
The legal basis is a ministerial decree, numac 2014011411, article 7 paragraph 1.
We flag this calculation as unverified, and the reason is worth knowing because it recurs across Europe. The reference framework we work from defines a margin as a share of the final selling price, but notes the Belgian figure as a markup of the form one plus the rate. Read as a margin, the back calculation factor is 0.69. Read as a markup, it is 0.7634. The difference is large enough to invalidate a comparison.
In Belgium the point is defused in practice, because the ex-factory price is available directly from the primary sources and the calculation is rarely needed. The notation question itself, however, has to be checked country by country wherever a margin figure is taken from a secondary table rather than from the national legal text.
The daily export carries two manufacturer level figures, and the distinction is easy to lose in a data model that keeps only one price column.
The official figure is the price as notified or approved. The second figure reflects what is actually in force for the pack, which can differ where a reduction has taken effect. Collapsing the two into a single field destroys information that cannot be recovered later, and it produces comparisons that are irreproducible, because a reader cannot tell which of the two your number came from.
The rule is the same one that applies to every European price source: keep the published fields separate, and derive a preferred value at query time rather than at import time. Import is where information is lost, and it is lost permanently.
Even with an official manufacturer price per pack, Belgium does not show what anyone actually paid. Rebates, tenders and contract prices sit below the published level here as they do everywhere in Europe. A Belgian ex-factory price is the cleanest kind of list price available on the continent, and it is still a list price.
For hospital procurement in particular, that distinction decides how the figure may be used: as a plausibility check and as a ceiling, not as a benchmark of what a comparable hospital paid.
The Belgian case isolates the three variables that actually decide how hard a country is.
Price level published. Belgium publishes at manufacturer level, so the derivation chain has zero steps and zero assumptions. Countries that publish at consumer level need tax removal plus one or two margin inversions, each with a legal basis and an effective date.
Pack identification. A pack specific code plus a structured quantity field is the whole game. Countries with free text pack descriptions need parsers, sampling and manual review.
Rights. The technical route and the legal route are separate questions, and the second one usually takes longer. Belgium is technically finished and legally half finished, which is a much better position than the reverse.
Against France, Belgium saves an entire class of work: no tax step, no numerical inversion of a margin schedule, no rule change scheduled in the near future. Against the Netherlands, the difference is legal rather than technical, because the Dutch route is blocked by a licence rather than by a formula. Against Germany, Belgium is simpler at the pack level and narrower in what the data says about negotiated outcomes.
That is why Belgium belongs early in any European build. It produces a usable manufacturer level dataset quickly, and it gives the pipeline a country where the published figure can be compared against derivations made elsewhere.
Belgium delivers what most of Europe withholds: an official manufacturer price per pack, daily, including products outside the reimbursed segment, with a clean pack level key. The remaining work is not analytical. It is a moving download link that has to be resolved on every run, and a redistribution right that has to be confirmed in writing rather than assumed.
Related reading: European Drug Pricing Database: how cross-border prices work and Pharma pricing Germany: how the system works, plus ex-factory price and list price vs net price.
pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Price coverage focuses on the DACH region and a number of further EU countries, with more countries following in the coming months.
